Skip to content
DataLookout
Menu

Ulcerative Colitis clinical trials

Get alerts when Ulcerative Colitis trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-10

What changed in the last 30 days

59 trials changed in the last 30 days: 3 stopped, 21 with notable changes, 35 with minor changes only.

  1. Notable: Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Recruitment opened Tanta UniversityPhase 2/3 NCT07820046
  2. Minor: Microbiome-targeted Diet Therapy in Ulcerative Colitis Start date moved earlier from Nov 9, 2026 to Nov 4, 2026 University of MinnesotaNot applicable NCT07520461
  3. Minor: 7 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep7 trials
    1. Minor: QUANTUM · Quest to Analyze One Thousand Humans Meditating Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Enrolling by Invitation Tobias Moeller-BertramNot specified NCT06583395
    2. Minor: Zuoqing SAN in Treating Ulcerative Colitis Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting The Second Affiliated Hospital of Anhui University of Traditional Chinese MedicinePhase 1/2 NCT06667934
    3. Minor: TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting Post Graduate Institute of Medical Education and Research, ChandigarhPhase 4 NCT06625450
    4. Minor: CSRRUC · Critical State of "Remission-Recurrence" of Ulcerative Colitis Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Beijing Hospital of Traditional Chinese MedicineNot specified NCT06694883
    5. Minor: ProZ-UC · ProLife 10 FORTE on Gut Microbiota Composition in UC Patients Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting University of PadovaNot applicable NCT06642883
    6. Minor: CONF-UC · Prognostic Value of Confocal Endomicroscopy in Ulcerative Colitis: the CONF-UC Study Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting FEDERICA FURFARONot applicable NCT06624579
    7. Minor: Acupuncture for Symptom Relief · Mild to Moderate Ulcerative Colitis Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting Guang'anmen Hospital of China Academy of Chinese Medical SciencesNot applicable NCT06615765
  4. Notable: MOVE-IT · MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease Enrolling by invitation only Odense University HospitalPhase 4 NCT06788340
  5. Notable: IB DYSPLASIA · Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study Recruitment opened Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNot specified NCT07719426
  6. Minor: EFFECT-1LAT · Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Trial completed PfizerNot specified NCT07177209
  7. Notable: Sub Study to Investigate the Safety and Tolerability of Aletekitug · Moderate To Severe Ulcerative Colitis Recruitment opened GlaxoSmithKlinePhase 1 NCT07747480
  8. Minor: AMETRINE-PEDS · Afimkibart (RO7790121) · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 26 → 29 locations Hoffmann-La RochePhase 3 NCT07158242
  9. Notable: GRACE · National GMA Post-market Clinical Follow-up Study Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2027 Adacyte Therapeutics SLNot specified NCT05636709
  10. Minor: Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease Trial completed Montefiore Medical CenterNot specified NCT06266663
  11. Notable: Tulisokibart · Crohn's Disease or Ulcerative Colitis (MK-7240-011) Primary endpoint(s) modified Merck Sharp & Dohme LLCPhase 3 NCT06651281
  12. Minor: ICONIC-UC · Protocol of Icotrokinra Therapy in Adult and Adolescent · Moderately to Severely Active Ulcerative Colitis Enrollment closed, study ongoing Janssen Research & Development, LLCPhase 3 NCT07196748
  13. Minor: DUET ENCORE-UC · JNJ-78934804 · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 279 → 318 locations Janssen Research & Development, LLCPhase 3 NCT07577856
  14. Minor: SKYLINE-LTE · Long-acting Antibodies Alone and in Combinations for IBD Trial sites expanded: 91 → 98 locations Spyre Therapeutics, Inc.Phase 2 NCT07652294
  15. Minor: GALILEO · Real-World Study of Guselkumab Persistence and Effectiveness · Crohn's Disease or Ulcerative Colitis Start date pushed from Oct 30, 2026 to Nov 15, 2026 Janssen-Cilag, S.A.Not specified NCT07848737
  16. Minor: GusTaCon · Continued Use of Guselkumab · Crohn's Disease and Ulcerative Colitis in Real World Setting Start date pushed from Oct 30, 2026 to Nov 12, 2026 Janssen Sciences Ireland UCNot specified NCT07746765
  17. Notable: Aquamin® · Ulcerative Colitis J-Pouch-associate Intestinal Inflammation Primary endpoint(s) modified Muhammad N Aslam, MDPhase 2 NCT07501078
  18. Minor: LEGACY · Registry of Humira® (Adalimumab) · Moderately to Severely Active Ulcerative Colitis (UC) Trial completed AbbVieNot specified NCT01848561
  19. Minor: COLOR UC · Brivekimig · Ulcerative Colitis Trial sites expanded: 66 → 69 locations SanofiPhase 2 NCT06975722
  20. Notable: ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool Enrollment increased: 220 → 1000 participants American Laboratory Products CompanyNot specified NCT06810518
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-04 NCT07916493 Effects of Different Physical Activity Strategies on Disease Activity of IBD Patients Szeged University new
2026-11-03 NCT07913347 Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT… Metagen Therapeutics, Inc. new Phase 1/2
2026-10-28 NCT07900945 Study of Single and Multiple Ascending Doses of CM551 in Healthy Participants Keymed Biosciences Co.Ltd new Phase 1
2026-10-09 NCT07869225 A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and… Equillium new Phase 1
2026-10-05 NCT07857447 The Effects of a Modified Mediterranean Diet on Ulcerative Colitis Patients University Hospital Sestre Milosrdnice new
2026-09-30 NCT07848737 A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With… Janssen-Cilag, S.A. new
2026-09-22 NCT07834515 Phase 1b Clinical Study in Patients With Active Ulcerative Colitis Thetis Pharmaceuticals LLC new Phase 1
2026-09-18 NCT07828886 Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD First Affiliated Hospital, Sun Yat-Sen University new
2026-09-17 NCT07824726 Ex Vivo Comparison Of Combination Versus Single Therapeutic Pathway Inhibition In Human… PhoenixLAB srls new
2026-09-15 NCT07819799 Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With… Attovia Therapeutics Inc new Phase 1

Active trials by phase

Early Phase 1
8
Phase 1
28
Phase 1/2
11
Phase 2
72
Phase 2/3
7
Phase 3
39
Phase 4
38
Not charted: 290 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Ulcerative Colitis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free